It was rolled out for the first time in Australia during the early months of 2015 and expanded to China, Hong Kong, Singapore, Arabia and New Zealand, with ongoing trials in the US market.
It has since expanded to China, Hong Kong, Singapore, Arabia, New Zealand and has ongoing trials in the US market. It was rolled out for the first time in Australia during the early months of 2015.
It was rolled out for the first time in Australia during the early months of 2015. It has since expanded to China, Hong Kong, Singapore, Arabia, New Zealand and has ongoing trials in the US market.
It was rolled out for the first time in Australia during the early months of 2015. It has since expanded to China, Hong Kong, Singapore, Arabia, New Zealand and has ongoing trials in the US market.